JAZZ
Jazz PublicANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull case is that Jazz combined a Q1 revenue and EPS beat with reaffirmed full-year guidance, strong Xywav, Epidiolex/Epidyolex and Zepzelca growth, substantial cash generation, and a dated zanidatamab PDUFA catalyst in August 2026.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.0.
What can break
Long-term debt was about $5.4 billion at March 31, 2026, which limits flexibility despite $2.9 billion of cash, cash equivalents and investments.
Momentum
89
Value
63
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $228.00 · Bull $255.00 · Bear $195.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $224.40
Why
Momentum89 · Δ7d -1.0
Value63 · Δ7d +0.4
Sentiment49 · Δ7d +6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.0
Δ21d
+5.1
Value
63
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.4
Sentiment
49
33% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+3.8
Why this grade
Composite grade A. Momentum 88.9 / Value 63.1 / Sentiment 49.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$14.6B
Beta
0.26
Shares Out
60.77M
P/E (TTM) · Derived
-41.1
P/S (TTM)
2.55
P/FCF (TTM)
8.55
Rev YoY
+6.7%
EPS YoY
+19.3%
Gross Margin
+88.5%
Op Margin
-11.9%
Net Debt
$3.12B
Current Ratio
1.65
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology